HRK and neoplasm: In patient-derived cell lines, we did not observe a clear trend in BCL2L1 (BCL-xL gene) nor HRK mRNAs (Supplementary Fig. S2), probably due to higher inter-tumor variability compared to the MCL-1:NOXA adaptation.